0

Evaluating ADS5102 (Amantadine) for the Treatment of Parkinson's Disease Patients With Dyskinesia

Thomas Müller, Wilfried Kuhn, Jan-Dominique Möhr

Expert Opin Pharmacother. 2019 Jul;20(10):1181-1187.

PMID: 31058557

Abstract:

Introduction: Amantadine is an old, antiviral compound that moderately ameliorates impaired motor behaviour in Parkinson's disease. Its current resurgence results from the novel retarded release amantadine hydrochloride formulation, ADS5102, which has also received approval for the treatment of levodopa-related involuntary movements known as dyskinesia. Areas covered: This non-systematic, narrative drug evaluation discusses the value of ADS5102 for patients with Parkinson's disease. ADS5102 is orally applied once daily in the evening. This capsule provides higher and more continuous amantadine plasma concentrations than conventional amantadine immediate release formulations with their two to three times daily intake plan. Expert opinion: ADS5102 was superior to placebo in clinical trials. They aimed for the amelioration of motor complications, particularly at 'OFF' periods and with dyskinesia in fluctuating levodopa treated patients with Parkinson's disease. Side effects and tolerability were similar to the well-known effects of conventional amantadine formulations. ADS5102 simplifies treatment and improves compliance problems in the long run. The marketing of ADS5102 outside the US will be complex for return of research costs and investments required for its manufacturing. Indeed, worldwide institutional price regulation scenarios often only consider new therapeutic mode of actions as being innovative as opposed to old drugs with improved pharmacokinetic behaviour.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP27244640 Levadopa Related Compound A Levadopa Related Compound A 27244-64-0 Price
AP935568 Amantadine Related Compound A Amantadine Related Compound A 935-56-8 Price
qrcode